Folic acid pathway modulation

"Folic acid pathway modulation" refers broadly to interventions that alter the activity of biochemical pathways dependent on folic acid and its derivatives. The core function of this network—often called one-carbon metabolism—is mediated by several enzymes that use reduced forms of dietary folates as cofactors for transferring single carbon units necessary for synthesizing nucleotides required in DNA/RNA production, amino acids like methionine from homocysteine, and S‑adenosylmethionine used in methylation reactions critical for gene expression control. Disruption or targeted inhibition of these pathways underlies several therapeutic strategies—most notably cancer chemotherapy using antifolate agents like methotrexate—which block cell proliferation by preventing nucleotide biosynthesis. Conversely, supplementation is crucial during periods requiring rapid cell division such as pregnancy or recovery from anemia. Because "Folic acid pathway modulation" describes an entire metabolic process involving many proteins/enzymes/receptors—not a discrete molecular entity—it is not considered a canonical drug target but rather a therapeutic concept encompassing multiple targets within cellular biochemistry.[1][3][5]

Other names

Folate metabolismFolic acid metabolic pathwayOne-carbon metabolism (folate-dependent)Folate pathway modulation

Drugs modulating the folic acid pathway act primarily by inhibiting key enzymes involved in one-carbon transfer reactions essential for nucleotide biosynthesis and methylation. For example, - Methotrexate inhibits dihydrofolate reductase, blocking conversion of dihydrofolic to tetrahydrofolic acid required for DNA synthesis.[3][6] - Pemetrexed inhibits multiple steps in purine/pyrimidine synthesis. - Leucovorin provides reduced folates that bypass DHFR inhibition. - Vintafolide delivers cytotoxins selectively to cells overexpressing the folate receptor α.[2]